SAN DIEGO, June 1, 2017 /PRNewswire/ -- NuVasive, Inc.
(NASDAQ: NUVA), a leading medical device company focused on
transforming spine surgery with minimally disruptive,
procedurally-integrated solutions, today announced Skip Kiil is joining the Company as executive
vice president, International. In this role, Mr. Kiil will oversee
the Company's international operations, reporting to NuVasive's
chairman and chief executive officer, Gregory T. Lucier, and serving on the Company's
executive leadership team.
Mr. Kiil brings to NuVasive more than 15 years of experience as
a global medical technologies and life sciences business leader. He
joins NuVasive from Alcon, a division of Novartis Corporation,
where he most recently served as surgical head, Europe, Middle
East, Africa and
Russia.
"I am excited to welcome Skip as a member of the NuVasive
executive leadership team," said Mr. Lucier. "Skip has led complex,
global commercial enterprises in Europe, the Middle
East, Africa, Japan, Asia
Pacific and the United
States within the healthcare and spine technology
industries. He brings significant strategic and operational
expertise in market entry and development and proficiency in
maintaining P&L responsibility, both of which are key elements
as we scale and expand our high-growth international channels. We
are pleased to have a global leader of Skip's caliber join
NuVasive's world-class leadership team at this time as we
accelerate past $1 billion in
revenue, enhance our international operations and continue to
change patients' lives around the world."
Mr. Kiil's career includes extensive corporate experience in
global markets. Prior to joining Alcon, Mr. Kill spent more than 12
years with Stryker Corporation, most recently as vice president and
general manager, Medical Surgical Group, based in London and Rome. In that capacity, he was responsible for
commercial operations for six strategic business units, including
Neuro Spine/ENT, Surgical Instruments, Endoscopy, Sports Medicine
and General Surgery/Visualization. Previously, as a senior leader
at Stryker, Mr. Kill was general manager, MedSurg Japan, based in
Tokyo. Prior to that, he had
increasing corporate development, sales and marketing roles for
Stryker in the United States. Mr.
Kiil received a Bachelor of Science in Kinesiology from
California State University, Fullerton
and a Masters of Business Administration from University of Michigan.
NuVasive is the third largest global spine technology company
with significant momentum to drive global growth and expansion as
the Company seeks to double its international market share in the
coming years. NuVasive is targeting international revenue growth at
20 percent or higher annually and scaling international operations
to support the Company's profitability expansion goals. The
Company's share-taking strategy and innovative product
introductions drove growth across all of its international
geographies including Europe, the
Middle East, Asia Pacific and Latin America in the first quarter of 2017,
leading to a 34% year-over-year increase on a reported basis in
international revenues, excluding the impact of currency.
About NuVasive
NuVasive, Inc. (NASDAQ: NUVA) is
a world leader in minimally invasive, procedurally-integrated spine
solutions. From complex spinal deformity to degenerative spinal
conditions, NuVasive is transforming spine surgery with innovative
technologies designed to deliver reproducible and clinically proven
surgical outcomes. NuVasive's highly differentiated,
procedurally-integrated solutions include access instruments,
implantable hardware and software systems for surgical planning and
reconciliation technology that centers on achieving the global
alignment of the spine. With $962
million in revenues (2016), NuVasive has an approximate
2,300 person workforce in more than 40 countries around the world.
For more information, please visit www.nuvasive.com.
Forward-Looking
Statements
NuVasive cautions you that
statements included in this news release that are not a description
of historical facts are forward-looking statements that involve
risks, uncertainties, assumptions and other factors which, if they
do not materialize or prove correct, could
cause NuVasive's results to differ
materially from historical results or those expressed or implied by
such forward-looking statements. The potential risks and
uncertainties which contribute to the uncertain nature of these
statements include, among others, risks associated with acceptance
of the Company's surgical products and procedures by spine
surgeons, development and acceptance of new products or product
enhancements, clinical and statistical verification of the benefits
achieved via the use of NuVasive's products (including
the iGA™ platform), the Company's ability to effectually manage
inventory as it continues to release new products, its ability to
recruit and retain management and key personnel, and the other
risks and uncertainties described
in NuVasive's news releases and periodic
filings with the Securities and Exchange
Commission. NuVasive's public filings with
the Securities and Exchange Commission are
available
at www.sec.gov. NuVasive assumes
no obligation to update any forward-looking statement to reflect
events or circumstances arising after the date on which it was
made.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/nuvasive-appoints-skip-kiil-as-executive-vice-president-international-300466719.html
SOURCE NuVasive, Inc.